Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Opinion|Videos|February 14, 2025

A case of a mother experiencing PPD while on low-dose SSRI

Melanie Barrett, MD; Anita Clayton, MD, and Carmen Kosicek, MSN, PMHNP-BC, discuss how a mother's persistent PPD symptoms despite SSRI treatment necessitated a comprehensive reevaluation of medication dosage, additional therapeutic interventions, and closer monitoring of treatment response to achieve better symptom control.

Episodes in this series

1 expert is featured in this series.

EP. 1 Overview of Postpartum Depression

1 expert is featured in this series.

EP. 2 Real-World Patient Perspective: Navigating Care for PPD

1 expert is featured in this series.

EP. 3 Real-World Patient Perspective: Breaking the Stigma of PPD and Seeking Support

1 expert is featured in this series.

EP. 4 Diagnostic Tools For PPD

1 expert is featured in this series.

EP. 5 Current and emerging treatments for PPD

1 expert is featured in this series.

EP. 6 A case of a mother experiencing PPD at 12 weeks postpartum

1 expert is featured in this series.

EP. 7 Treatment approach for a mother experiencing PPD at 12 weeks postpartum

1 expert is featured in this series.

EP. 8 A case of a mother experiencing PPD while on low-dose SSRI

1 expert is featured in this series.

EP. 9 Treatment approach for a mother experiencing PPD already on SSRI

postpartum depression

EP. 10 Panel Discusses Screening, Treatment, and Challenges for Postpartum Depression

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

5 experts are featured in this series

Differentiating Agitation from Depression, Anxiety, and Psychosis

ByMarwan Sabbagh, MD, FAAN, FANA,Amita R. Patel, MD, CMD, MHA, CPE,Erin Crown, MHS, PA-C, Psych-CAQ,David Liporace, DO,Laura Melaro, DNP, APRN, FNP-BC, PMHNP-BC

September 4th 2026

5 experts are featured in this series

Agitation Associated with Dementia Due to Alzheimer’s Disease: How Common Is It, and How Does It Present?

ByMarwan Sabbagh, MD, FAAN, FANA,Amita R. Patel, MD, CMD, MHA, CPE,Erin Crown, MHS, PA-C, Psych-CAQ,David Liporace, DO,Laura Melaro, DNP, APRN, FNP-BC, PMHNP-BC

September 4th 2026

court of public opinion

Insanity Trials and The Court of Popular Opinion

ByAnuradha Shetty MD,Susan Hatters Friedman, MD, MSt, DFAPA

August 28th 2026

psychiatry on trial

Psychiatry on Trial: Are Psychiatrists Responsible for Their Patients’ Criminal Behavior?

ByFernando Espí Forcén, MD, PhD,Susan Hatters Friedman, MD, MSt, DFAPA

August 27th 2026

andranik123/Adobe Stock

Morning Rounds: News From August 3-9

ByJessica Walters

August 10th 2026

Latest CME

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

Trending on Psychiatric Times

Repurposing Dopamine Agonist Pramipexole for Disabling Anhedonia

GLP-1 Receptor Agonists Linked to Lower Mortality, Cardiovascular Events in Serious Mental Illness

Brain Trust: Anita H. Clayton, MD, on Diagnosing and Treating Sexual Dysfunction

When Treatment-Resistant Depression Means Mismatched: Rethinking Difficult-to-Treat Depression

The Year So Far in GLP-1s: What Psychiatric Clinicians Need to Know